Kazia Therapeutics (ASX:KZA) - CEO, Dr James Garner
CEO, Dr James Garner
Source: Kazia Therapeutics/Twitter
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Oncology-focused drug development company Kazia Therapeutics (KZA) establishes an “at-the-market” equity program, with Oppenheimer & Co acting as sales agent
  • Under the ATM, Kazia may offer and sell via Oppenheimer up to US$35 million (A$48.7 million) worth of Kazia shares in the form of American Depository Shares (ADSs)
  • Each ADS represents 10 ordinary shares
  • Kazia says sales of ADSs under the ATM may be made from time to time at its sole discretion
  • KZA shares down 9.22 per cent to 98.5 cents

Oncology-focused drug development company Kazia Therapeutics (KZA) has established an “at-the-market” (ATM) equity program.

The company said Oppenheimer & Co will act as sales agent.

Under the ATM, Kazia may offer and sell via Oppenheimer up to US$35 million (A$48.7 million) worth of Kazia shares.

The stock will be in the form of American Depository Shares (ADSs), with each ADS representing 10 ordinary shares.

Sales of ADSs under the ATM may be made from time to time, with the timing and volume of any sales to be determined by Kazia at its sole discretion, based on a variety of factors.

“ATM facilities are a common financing instrument for Nasdaq-listed biotech companies,” Kazia Chairman Iain Ross said.

“We consider it prudent capital management for Kazia to have access to such a facility, so that it may respond most efficiently and most cost effectively to emerging investor demand.”

Kazia currently intends using any net proceeds from the ATM primarily for general
corporate purposes including working capital and capital expenditures and for expenses related to research, clinical development and commercial efforts.

Funds may also be used for potential acquisitions or investments, though the company noted it had no current commitments or agreements with respect to any acquisitions.

KZA shares were down 9.22 per cent to 98.5 cents close to the end of today’s trading session.

KZA by the numbers
More From The Market Herald
Countplus (ASX:CUP) - Incoming CEO, Hugh Humphrey

" Hugh Humphrey appointed CEO of Countplus (ASX:CUP)

Investment services company CountPlus (ASX:CUP) has appointed Hugh Humphrey as the company's CEO, effective July 1.

" ASX employee tests positive for Covid-19

The ASX says an employee has contracted Covid-19.

" ASIC launches official investigation into ASX market outage

The ASX has confirmed today it is officially under investigation from the Australian Securities and Investments…

" ASX sheds more light on last week’s market tech failure

The Australian Securities Exchange has shed some more light on the nature of last week's market…